PRDS PARDES BIOSCIENCES INC

Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that management will participate in a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 7:30 a.m. PT / 10:30 a.m. ET in New York City.

A live audio webcast of the event will be available in the Investors section of Pardes’ website at , with an archived replay available for 30 days following the event.

About Pardes Biosciences, Inc.

Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems, starting with COVID-19. We are dedicated to discovering and developing potent and easy-to-prescribe oral antiviral drug candidates so that patients everywhere can get well sooner. For more information, please visit .



Availability of Other Information about Pardes Biosciences

Pardes Biosciences intends to use the Investors page of its website () as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Pardes Biosciences’ Investors website, in addition to following Pardes Biosciences’ press releases, Securities and Exchange Commission (SEC) filings, public conference calls, presentations and webcasts.

Investor Contacts:

Patrick O'Brien

Stephen Jasper

Gilmartin Group

(858) 525-2047



EN
12/09/2022

Underlying

PRDSPARDES BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PARDES BIOSCIENCES INC

 PRESS RELEASE
Free
PRDS PARDES BIOSCIEN...

Pardes Biosciences Announces Closing of Tender Offer

Pardes Biosciences Announces Closing of Tender Offer CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes’ outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent value right (each, a CVR and each CVR tog...

August 31, 2023 1 EN
 PRESS RELEASE
Free
PRDS PARDES BIOSCIEN...

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific...

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights CARLSBAD, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) today announced that it has entered into a definitive merger agreement whereby MediPacific, Inc. (Purchaser) will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amount of the Company’s net cash at closing, plus a non...

July 17, 2023 1 EN
 PRESS RELEASE
Free
PRDS PARDES BIOSCIEN...

Pardes Biosciences Reports First Quarter 2023 Financial Results

Pardes Biosciences Reports First Quarter 2023 Financial Results CARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended March 31, 2023. “As previously announced this year, Pardes Biosciences has initiated a process to evaluate strategic alternatives to maximize shareholder value that may potentially result in changes to our business strategy,” said Thomas G. Wiggans, Chief Executive Officer and Chair of Pardes Biosciences. First Quarter 2023 Financial Results Pardes reported a net loss of $1...

May 5, 2023 1 EN
 PRESS RELEASE
Free
PRDS PARDES BIOSCIEN...

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evalu...

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19 Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir vs. placebo Otherwise healthy, vaccinated adults without risk factors for progression to severe disease experienced rapid clearance of SARS-CoV-2 virus and evidence of rapid alleviation of targeted and key COVID-19 symptoms independent of treatment arm Based on these results, Pardes to suspend fur...

April 3, 2023 1 EN
 PRESS RELEASE
Free
PRDS PARDES BIOSCIEN...

Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial...

Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Data from ongoing Phase 2 trial evaluating pomotrelvir (formerly known as PBI-0451) for the treatment of COVID-19 expected in the coming weeks Cash to fund operations for the next twelve months CARLSBAD, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing pomotrelvir as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment of COVID-19, today reported financi...

March 14, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch